Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Angiogenesis gene therapy - Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
Autore:
Rosengart, TK; Lee, LY; Patel, SR; Sanborn, TA; Parikh, M; Bergman, GW; Hachamovitch, R; Szulc, M; Kligfield, PD; Okin, PM; Hahn, RT; Devereux, RB; Post, MR; Hackett, NR; Foster, T; Grasso, TM; Lesser, ML; Isom, OW; Crystal, RG;
Indirizzi:
Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Div Pulm & Crit Care, New York, NY 10021 USA Cornell Univ New York NY USA 10021 lm & Crit Care, New York, NY 10021 USA Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Dept Cardiothorac Surg, New York, NY 10021 USA Cornell Univ New York NY USA 10021 diothorac Surg, New York, NY 10021 USA Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Div Cardiol, NewYork, NY 10021 USA Cornell Univ New York NY USA 10021 ll, Div Cardiol, NewYork, NY 10021 USA N Shore Univ Hosp, Div Biostat, Manhasset, NY USA N Shore Univ Hosp Manhasset NY USA Hosp, Div Biostat, Manhasset, NY USA GenVec Inc, Rockville, MD USA GenVec Inc Rockville MD USAGenVec Inc, Rockville, MD USA
Titolo Testata:
CIRCULATION
fascicolo: 5, volume: 100, anno: 1999,
pagine: 468 - 474
SICI:
0009-7322(19990803)100:5<468:AGT-PI>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENDOTHELIAL GROWTH-FACTOR; CYSTIC-FIBROSIS; DELIVERY; VIVO; OCCLUSION; PERFUSION; ISCHEMIA; HEARTS; LIVER;
Keywords:
angiogenesis; gene therapy; genetics; coronary disease; ischemia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Crystal, RG Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Div Pulm & Crit Care, New York, NY 10021 USA Cornell Univ New York NY USA 10021 re, New York, NY 10021 USA
Citazione:
T.K. Rosengart et al., "Angiogenesis gene therapy - Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease", CIRCULATION, 100(5), 1999, pp. 468-474

Abstract

Background-Therapeutic angiogenesis, a new experimental strategy for the treatment of vascular insufficiency, uses the administration of mediators known to induce vascular development in embryogenesis to induce: neovascularization of ischemic adult tissues. This report summarizes a phase I clinicalexperience with a gene-therapy strategy that used an E1(-)E3(-) adenovirus(Ad) gene-transfer vector expressing human vascular endothelial growth factor (VEGF) 121 cDNA (Ad(GV)VEGF121.10) to induce therapeutic angiogenesis in the myocardium of individuals with clinically significant: coronary artery disease. Methods and Results-Ad(GV)VEGF121.10 was administered to 21 individuals bydirect myocardial injection into an area of reversible ischemia either as an adjunct to conventional coronary artery bypass grafting (group A, n=15) or as sole therapy via a minithoracotomy (group B, n=6), There was no evidence of systemic or cardiac-related adverse events related to vector administration. Tn both groups, coronary angiography and stress sestamibi scan assessment of wall motion 30 days after therapy suggested improvement in the area of vector administration. All patients reported improvement in angina class after therapy. In group B, in which gene transfer was the only therapy, treadmill exercise assessment suggested improvement in most individuals. Conclusions-The data are consistent with the concept that direct myocardial administration of Ad(GV)VEGF121.10 to individuals with clinically significant coronary artery disease appears to be well tolerated, and initiation of phase LI evaluation of this therapy is warranted.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 08:36:55